Dr. Dyer brings a wealth of medical expertise and business skills to Alimera Sciences, Inc.
FREMONT, CA: Alimera Sciences, Inc. (ALIM) (Alimera), a market leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces David Dyer, M.D. to its leadership team. Dr. Dyer brings his expertise in medicine and business to the company while still seeing patients in his clinic in Kansas City, Missouri.
“I am very excited that Dr. Dyer is joining our team in this newly created position as he brings the insights of a seasoned practicing retina specialist and accomplished business owner to Alimera,” says Rick Eiswirth, Alimeras President and Chief Executive Officer. “Dr. Dyer’s intricate retina knowledge, his years of practice experience, and his understanding of novel technologies will play an instrumental role in achieving our vision of being the place to be in retina, focused solely on the needs of retina specialists and their patients.”
“The opportunity to work with the Alimera team to develop the corporate vision into a reality and emphasize ILUVIENs ability to provide long-term control of recurrence of disease brings continued significant potential in both the U.S. and international markets,” says Dr. Dyer “Additionally, the Phase 4 NEW DAY Study is an exciting and needed comparison of long-term steroid versus anti-VEGF treatment. The company continues to grow its international footprint, creating a platform for potential future products.”
Dr. Dyer founded Retina Associates, LLC in 1999, one of the most well-established and advanced practices in the area dedicated to diagnosing and treating diseases of the retina, macula, and vitreous. Dr. Dyer also founded TreVia Digital Health, LLC, a health care company that provides technology-enabled services, including digital diabetic retinopathy screenings, for the diagnosis and prevention of diabetic retinopathy complications.
A board-certified retina specialist, Dr. Dyer, obtained his undergraduate and medical degrees from George Mason University. He completed his ophthalmology residency at Storm Eye Institute. In addition, he completed his retina fellowships at The Wilmer Ophthalmological Institute and Rush-Presbyterian St. Luke's Medical Center in Chicago, Illinois.